Page last updated: 2024-11-11

u 75875

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

U 75875: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5479205
CHEMBL ID3350189
SCHEMBL ID15532017
MeSH IDM0181192

Synonyms (19)

Synonym
u75875
u 75875
noa-his-cha.psi.[chohchoh]val-ile-amp
112190-24-6
(2r,3r,4r,5s)-6-cyclohexyl-3,4-dihydroxy-5-[[(2s)-3-(1h-imidazol-4-yl)-2-[[2-(1-naphthyloxy)acetyl]amino]propanoyl]amino]-2-isopropyl-n-[(1s,2s)-2-methyl-1-(2-pyridylmethylcarbamoyl)butyl]hexanamide
l-idonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[[(2s)-3-(1h-imidazol-4-yl)-2-[[(1-naphthalenyloxy)acetyl]amino]-1-oxopropyl]amino]-2-(1-methylethyl)-n-[(1s,2s)-2-methyl-1-[[(2-pyridinylmethyl)amino]carbonyl]butyl]
u-75875
1HIV
(2r,3r,4r,5s)-6-cyclohexyl-3,4-dihydroxy-5-[[(2s)-3-(1h-imidazol-5-yl)-2-[(2-naphthalen-1-yloxyacetyl)amino]propanoyl]amino]-n-[(2s,3s)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]-2-propan-2-ylhexanamide
l-idonamide, 6-cyclohexyl-2,5,6-trideoxy-5-((3-(1h-imidazol-4-yl)-2-(((1-naphthalenyloxy)acetyl)amino)-1-oxopropyl)amino)-2-(1-methylethyl)-n-(2-methyl-1-(((2-pyridinylmethyl)amino)carbonyl)butyl)-, (1(1s,2s),5(s))-
noa-his-cha-psi(ch(oh)ch(oh))-val-ile-amp
pnu-75875
1-naphthoxyacetyl-histidyl-5-amino-6-cyclohexyl-3,4-dihydroxy-2-isopropylhexanoyl-isoleucyl-2-aminopyridine
SCHEMBL15532017
DTXSID20149940
CHEMBL3350189 ,
bdbm50212827
(2r,3r,4r,5s)-5-((s)-3-(1h-imidazol-5-yl)-2-(2-(naphthalen-1-yloxy)acetamido)propanamido)-6-cyclohexyl-3,4-dihydroxy-2-isopropyl-n-((2s,3s)-3-methyl-1-oxo-1-((pyridin-2-ylmethyl)amino)pentan-2-yl)hexanamide
AKOS040754284
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00100.00100.00100.0010AID977610
Chain B, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00100.00100.00100.0010AID977610
Exoribonuclease H Human immunodeficiency virus 2IC50 (µMol)0.03000.00050.01520.0300AID161864
Protease Human immunodeficiency virus 1IC50 (µMol)0.37550.00010.22487.3200AID162042; AID162045
Protease Human immunodeficiency virus 1Ki0.00140.00000.04433.1000AID160452; AID160455; AID160616; AID161862; AID80894
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1Kd0.00050.00010.04120.5770AID162706
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID80894Tested for inhibitory activity against HIV-1 protease1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities.
AID162042Inhibition of HIV-1 protease in 5%DMSO1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID155619Inhibition of p24 expression in HIVD34-infected PBMC assay on day 4 at concentration of 1 nM1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID160767Association rate constant for the interaction between inhibitor and HIV-1 protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID46493Cytotoxicity on COS A6 cells in the absence of 10% fetal calf serum(FCS)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID160766Dissociation rate constant for the interaction between inhibitor and HIV-1 protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID161864Inhibition of HIV-2 protease in 5%DMSO1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID162706Equilibrium constant for the interaction between inhibitor and HIV-1 Protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID160455Inhibition constant against HIV-1 Protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID160452In vitro inhibitory activity against biotinylated human HIV-1 protease1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID161862Inhibitory activity against HIV-1 protease1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity.
AID155621Inhibition of p24 expression in HIVD34-infected PBMC assay on day 4 at concentration of 100 nM1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID160616Binding affinity for HIV-1 protease1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
HIV protease: a novel chemotherapeutic target for AIDS.
AID47062Inhibition of p24 expression was measured at 1 uM using vVK/CV-1 assay1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID155630Inhibition of viral RNA in HIVD34-infected PBMC assay on day 4 at concentration of 10 nM1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID155620Inhibition of p24 expression in HIVD34-infected PBMC assay on day 4 at concentration of 10 nM1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID155628Inhibition of viral RNA in HIVD34-infected PBMC assay on day 4 at a concentration of 100 nM1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID152947Tested for the inhibition of p24 production in HIV-1 IIIB infected human peripheral blood mononuclear cells (PBMC)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities.
AID162045Inhibition of HIV-1 protease in 10% fetal calf serum(FCS)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID155629Inhibition of viral RNA in HIVD34-infected PBMC assay on day 4 at concentration of 1 nM1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
AID152944Tested for the inhibition of p24 production in HIV-1 IIIB infected human peripheral blood mononuclear cells (PBMC)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1992Protein science : a publication of the Protein Society, Aug, Volume: 1, Issue:8
Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
AID1811Experimentally measured binding affinity data derived from PDB1992Protein science : a publication of the Protein Society, Aug, Volume: 1, Issue:8
Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's19 (86.36)18.2507
2000's3 (13.64)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]